12Jan
Sanofi to Acquire Kymab for up to $1.45 Billion
Sanofi announced that it has entered into an agreement to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones. The acquisition will give Sanofi full global rights to Kymab’s KY1005, which binds to OX40-Ligand and has the potential to treat a wide variety of...
By:
Goodwin
Related
Q: Are there any new cases involving Pennsylvania’s Medical Marijuana Act in the context of employm...
Read More >
Key Takeaways - - On July 31, 2020, the U.S. Treasury Department, as chair of the Committee on Fore...
Read More >
The U.S. Court of Appeals for the Third Circuit has ruled that a Philadelphia city ordinance that pr...
Read More >
On March 19, 2020, Governor Newsom issued a “Safer at Home” Order, which generally permits constru...
Read More >
DOJ is catching up to compliance officers and evolving best practices. Say what you want, DOJ is be...
Read More >
On August 8, 2019, the U.S. Department of Labor announced that it issued three new opinion letters. ...
Read More >